Durvalumab prolongs overall survival whereas radiation dose escalation over 66 Gy improves long-term local control in unresectable NSCLC stage III: Updated analysis of the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
- F Zehentmayr (Author)
- P Feurstein (Author)
- E Ruznic (Author)
- B Langer (Author)
- B Grambozov (Author)
- M Klebermass (Author)
- A Purevdorj (Author)
- G Gruber (Author)
- D Minasch (Author)
- M Heilmann (Author)
- B Breitfelder (Author)
- C Steffal (Author)
- G Gastinger-Grass (Author)
- K Kirchhammer (Author)
- M Kazil (Author)
- Stranzl-Lawatsch, H. (Author)
- K Dieckmann (Author)
Activity: Talk, presentation or poster › Poster